Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
出版年份 2019 全文链接
标题
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 4, Pages 824
出版商
MDPI AG
发表日期
2019-02-15
DOI
10.3390/ijms20040824
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Causes of death in long-term survivors of non-small cell lung cancer: A regional surveillance, epidemiology, and end results study
- (2018) AymanO Soubani et al. Annals of Thoracic Medicine
- STAT3, stem cells, cancer stem cells and p63
- (2018) Michaela Galoczova et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
- (2018) Hyojin Kim et al. PLoS One
- Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
- (2018) Bingjia Li et al. OncoTargets and Therapy
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
- (2017) Kazuki Takada et al. LUNG CANCER
- HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
- (2017) Francisco Perea et al. Oncotarget
- PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer
- (2017) Cuiling Zhou et al. Oncotarget
- Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
- (2017) Edwin R. Parra et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer
- (2017) Xiaohua Shi et al. Scientific Reports
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
- (2017) Minghui Zhang et al. Scientific Reports
- P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
- (2016) Roy S. Herbst et al. Journal of Thoracic Oncology
- Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
- (2016) Kazuki Takada et al. Journal of Thoracic Oncology
- Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
- (2016) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
- (2016) Masaki Shimoji et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
- (2015) A. Wang et al. EJSO
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis
- (2015) Fei Zhou et al. LUNG CANCER
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis
- (2015) Anyuan Zhong et al. OncoTargets and Therapy
- B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
- (2015) Yixiang Mao et al. Oncotarget
- PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
- (2015) Lars Henning Schmidt et al. PLoS One
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Lung Cancer: Epidemiology, Etiology, and Prevention
- (2011) Charles S. Dela Cruz et al. CLINICS IN CHEST MEDICINE
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search